SEQUENCE LISTING

<110> Applied Research Systems ARS Holding N.V.

<120> NOVEL CXCL8 ANTAGONISTS

<130> WO932

<160> 6

<170> PatentIn version 3.1

<210> 1
<211> 297
<212> DNA
<213> homo sapiens
<220>
<223> Human CXCL8 coding sequence

<400> 1
atgacttcca agctggccgt ggctctcttg gcagccttcc tgatttctgc agctctgtgt 60

gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac 120

tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac 180

tgcgccaaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc 240

aaggaaaact gggtgcagag ggttgtggag aagtttttga agagggctga gaattca 297

<210> 2
<211> 72
<212> PRT
<213> Homo sapiens
<220>
<223> Mature human CXCL8

<400> 2

Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
1 5 10 15

Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro
20 25 30

His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu
35 40 45

Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Lys
50 55 60

Phe Leu Lys Arg Ala Glu Asn Ser
65 70

<210> 3
<211> 297
<212> DNA
<213> Synthetic construct
<220>
<223> CXCL8-1B3 coding sequence

<400> 3
atgacttcca agctggccgt ggctctcttg gcagccttcc tgatttctgc agctctgtgt 60

gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac 120

tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac 180

tgcgccaaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc 240

aaggaaaact gggtgcaggc ggttgtggag gcgtttttgg cgagggctga gaattca 297

<210> 4
<211> 72
<212> PRT
<213> Synthetic construct
<220>
<223> Mature CXCL8-1B3

<400> 4

Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
1 5 10 15

Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro
20 25 30

His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu
35 40 45

Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Ala Val Val Glu Ala
50 55 60

Phe Leu Ala Arg Ala Glu Asn Ser
65 70

<210> 5
<211> 297
<212> DNA
<213> Synthetic construct
<220>
<223> CXCL8-2B3 coding sequence

<400> 5

atgacttcca agctggccgt ggctctcttg gcagccttcc tgatttctgc agctctgtgt 60

gaaggtgcag ttttgccaag gagtgctaaa gaacttagat gtcagtgcat aaagacatac 120

tccaaacctt tccaccccaa atttatcaaa gaactgagag tgattgagag tggaccacac 180

tgcgccaaca cagaaattat tgtaaagctt tctgatggaa gagagctctg tctggacccc 240

aaggaaaact gggtgcagag ggttgtggag gcgtttttgg cggcggctga gaattca 297

<210> 6
<211> 72
<212> PRT
<213> Synthetic construct
<220>
<223> Mature CXCL8-2B3

<400> 6

Ser Ala Lys Glu Leu Arg Cys Gln Cys Ile Lys Thr Tyr Ser Lys Pro
1 5 10 15

Phe His Pro Lys Phe Ile Lys Glu Leu Arg Val Ile Glu Ser Gly Pro
20 25 30

His Cys Ala Asn Thr Glu Ile Ile Val Lys Leu Ser Asp Gly Arg Glu
35 40 45

Leu Cys Leu Asp Pro Lys Glu Asn Trp Val Gln Arg Val Val Glu Ala
50 55 60

Phe Leu Ala Ala Ala Glu Asn Ser
65 70